+39 02 610346.1 - info@newron.com


Our balanced and robust pipeline is comprised of drug candidates targeting various indications in CNS and pain.

  • Xadago® (safinamide) is the first new chemical entity approved for more than a decade in EU, in Switzerland and in the U.S. as adjunctive therapy in Parkinson’s disease (PD). The product has been licensed to Zambon Group and Meiji Seika Pharma with additional commercialization partners US WorldMeds in the U.S., Seqirus in Australia and New Zealand, Valeo Pharma for Canada and Medison for Israel.
  • Evenamide is a voltage-gated sodium channel blocker developed from Newron’s proprietary ion channel research program. It has proven safe and well-tolerated and has shown evidence of efficacy in significantly improving symptoms of psychosis compared with placebo when added to two of the most commonly prescribed atypical antipsychotics in patients with chronic schizophrenia, in a Phase II study. The product has the potential to become the first add-on therapy for the treatment of schizophrenia.
  • Sarizotan is a highly selective compound modulating the activity of specific serotonin or dopamine receptors in the brain. It is currently in a the potentially pivotal STARS study for Rett syndrome and has the potential to become the first drug approved for this orphan disease, and the first therapy to become independently commercialized by Newron.
  • Ralfinamide is a novel, well-tolerated small molecule for the treatment of neuropathic pain (rare indication).